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ABSTRACT
The incidence of thyroid carcinoma is rapidly increasing. Although generally 
associated with good prognosis, a fraction of thyroid tumors are not cured by standard 
therapy and progress to aggressive forms for which no effective treatments are 
currently available. In order to identify novel therapeutic targets for thyroid carcinoma, 
we focused on the discovery of genes essential for sustaining the oncogenic phenotype 
of thyroid tumor cells, but not required to the same degree for the viability of normal 
cells (non-oncogene addiction paradigm). We screened a siRNA oligonucleotide library 
targeting the human druggable genome in thyroid cancer BCPAP cell line in comparison 
with immortalized normal human thyrocytes (Nthy-ori 3–1). We identified a panel of 
hit genes whose silencing interferes with the growth of tumor cells, while sparing that 
of normal ones. Further analysis of three selected hit genes, namely Cyclin D1, MASTL 
and COPZ1, showed that they represent common vulnerabilities for thyroid tumor cells, 
as their inhibition reduced the viability of several thyroid tumor cell lines, regardless 
the histotype or oncogenic lesion. This work identified non-oncogenes essential 
for sustaining the phenotype of thyroid tumor cells, but not of normal cells, thus 
suggesting that they might represent promising targets for new therapeutic strategies.
INTRODUCTION
The incidence of thyroid cancer (TC), the 
most common endocrine malignancy, has increased 
significantly over the last few decades [1]. All TCs, 
except medullary thyroid carcinoma, are derived from 
thyroid follicular cells. Differentiated tumors, namely 
papillary and follicular carcinoma (PTC and FTC, 80% 
and 10% of cases, respectively) are generally cured by 
current treatment involving surgery, thyroid hormone and 
radioactive iodine therapy; however, they occasionally 
progress into undifferentiated, more aggressive and lethal 
carcinomas. Poorly differentiated (PDTC) and anaplastic 
(ATC) carcinoma, although rare, are the most clinically 
aggressive TCs; for ATC patient the survival is reduced to 
few months [2].
Genetic studies performed in the last 25 years have 
dissected the molecular bases of TC. PTC is associated 
with a high frequency of deregulation of RTK/RAS/
RAF/MAPK pathway [3]. This includes oncogenic 
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rearrangements of the RET and NTRK1 receptors, and 
point mutations in the BRAF and RAS genes, with 
the BRAFV600E as the most frequent PTC alteration. 
The genetic landscape of PTC has been very recently 
expanded by integrated genomic characterization studies 
which identified several novel driver alterations [4]. 
FTC is associated with RAS mutations and PAX8/PPARγ 
rearrangements. RAS mutations are common in PDTC. 
ATC is associated with mutations of BRAF, RAS, TP53, 
PTEN, and PIK3CA. The identification and functional 
characterization of differentially expressed genes and 
miRNAs have also contributed to the understanding of 
thyroid tumor biology, and provided important diagnostic/
prognostic tools [5–8].
Molecular findings have been translated into the 
clinical setting, leading to clinical experimentation of 
agents targeting thyroid oncoproteins or downstream 
pathways [9]. Several kinase inhibitors, primarily targeting 
BRAF and angiogenic kinases, are under evaluation in 
clinical trials [10]. Nevertheless, no effective targeted 
therapies are currently available for aggressive TC that are 
not curable by the standard therapeutic approaches.
The traditional approach for cancer target discovery 
is based on the identification of driver oncogenes through 
the characterization of the molecular alterations of primary 
tumors. However, according to the concept of “non-
oncogene addiction” (NOA), the uncontrolled growth 
of cancer cells often relies on normal genes, that are 
not themselves oncogenes or otherwise mutated, whose 
activity is essential for tumor cells but not required to the 
same extent by normal cells [11]. NOA genes cannot be 
identified by genetic approaches aimed at identifying gene 
mutation/aberrancy, but rather by large-scale siRNA-based 
functional screening, a strategy which is nowadays widely 
used for the identification of tumor cell vulnerabilities to 
be explored for therapeutic purposes [12–15].
In order to identify novel, unforeseen molecular 
targets for thyroid carcinoma, in this study we have 
undertaken the screening of a siRNA oligonucleotide 
library in tumor (BCPAP) and normal (Nthy-ori 3–1) 
thyroid cell lines, and we have identified a set of genes 
whose silencing reduces the growth of tumor cells, 
while sparing growth of non-transformed cells of the 
same tissue origin. Among the top ranked genes, we 
selected Cyclin D1 (CCND1), MASTL and COPZ1. All 
of them passed a secondary confirmation study, which 
unequivocally demonstrated the dependency of BCPAP 
cells upon their activity. Interestingly, we found that 
silencing of Cyclin D1, MASTL and COPZ1 inhibits the 
growth of several further thyroid tumor cell lines.
RESULTS
Druggable genome siRNA screening
To identify genes affecting growth of thyroid tumor 
cells, we conducted an RNAi-based phenotypic screening, 
examining effects on cell growth. The papillary thyroid 
carcinoma BCPAP cell line, carrying the BRAFV600E 
mutation, and the immortalized normal human thyrocyte 
Nthy-ori 3–1 cell line were transfected with a siRNA 
library containing 25139 siRNA oligos targeting about 
9000 potentially “druggable” genes (3 duplexes/gene, 
on average), and with a non-targeting siRNA (siNT) and 
a siRNA targeting the proteasomal subunit PSMC3 as 
negative and positive controls, respectively. Cells were 
transfected at low density in 96-well plates and colony 
formation assay (CFA) was performed after 7 (Nthy-
ori 3–1) or 8 (BCPAP) days. Images of a representative 
plate for each of these lines are shown in Figure 1A. We 
preferred CFA to short-term (48–72 hours) proliferation 
assay, since it allows the detection of long-term 
consequences of “weak” phenotypes (our unpublished 
results). The screening results are shown in Figure 1B: 
scatter plots represent the fluorescence signal, derived 
from CFA acquisition, normalized with respect to siNT 
(% siNT) of Nthy-ori 3–1 and BCPAP cells transfected in 
duplicate with the library siRNA oligos (the complete list 
is reported in Table S1). Of note, the uneven distribution 
of data across graph diagonal denotes slightly higher 
transfection efficiency for Nthy-ori 3–1 than for BCPAP. 
Genes essential for cell viability of BCPAP, but not Nthy-
ori 3–1 cells, were identified through the “d parameter” 
(defined in Materials and Methods). d values close to 0 
denote preferential inhibition of BCPAP cell proliferation 
with respect to Nthy-ori 3–1. Based on data distribution, a 
threshold of -3σ (corresponding to d = 47.2) was applied 
to define differentially active hits: 398 siRNA oligos 
(1.58%), targeting 386 genes, were found to be below 
this threshold and thus were defined as “differential hits” 
(Figure 1C; hit list is reported in Table S2). A significant 
preferential activity towards BCPAP cells was observed 
for 12 genes with 2 oligos out of 3, and for the remaining 
374 genes with 1 oligo out of 3; the latter include BRAF, 
consistent with the notion that BCPAP cells are addicted 
to BRAFV600E oncogene [16]. No genes emerged with 
3/3 oligos among hits. Functional annotation clustering 
analysis was performed on the 386 gene list (382 
DAVID IDs), using Gene Ontology-Biological Process 
(GO-BP) and Gene Ontology–Molecular Function 
(GO-MF) annotation terms and medium classification 
stringency. A significant Enrichment score (>1.3) was 
found in 15 out of the 117 annotation clusters that 
were globally identified. The top ranked GO-terms, 
representative for the 15 significant clusters, have been 
reported in Figure S1A.
By setting an arbitrary threshold of 20% colony 
growth with respect to siNT controls, we identified 1695 
siRNA oligonucleotides (6.74%) capable of inhibiting cell 
growth both in BCPAP and Nthy-ori 3–1, therefore defined 
as “lethal hits” (Figure 1C). Two hundred and seventeen 
genes emerged as indiscriminately lethal hits with 
2/3 (163) or 3/3 (54) oligonucleotides (Table S3). Most of 
them encode proteins involved in fundamental processes, 
Oncotarget34631www.impactjournals.com/oncotarget
and some, such as the kinases PLK1, WEE1, AURKB and 
several proteasome subunits, have previously been shown 
to be essential for cell survival, emerging as top-ranking 
lethal hits in RNAi-mediated phenotypic proliferation 
screens in different tumor cell lines [14, 17, 18].
Confirmation of differentially active hits
Eightyfour siRNA oligonucleotides, targeting 
28 genes, were selected for confirmatory studies. Hits 
were prioritized for technical confirmation based on d 
values of individual oligos and on specific interest of 
identifying candidate druggable target genes. siRNAs 
were picked from library plates and transfected manually 
in triplicate on Nthy-ori 3–1 and BCPAP cells using 
the same experimental conditions as employed in 
primary screening. In these experiments a threshold of 
-2σ (corresponding to d = 49.8) was applied to define 
oligos with significantly low d values, i.e. displaying 
differential activity. We considered equally confirmed 
any siRNA oligos that in confirmation experiments gave 
the same phenotype of the screening, including the ones 
inactive or lethal for both cell lines. Figure 2A shows the 
comparison between primary screening and confirmation 
results. Eighteen out of 35 siRNA oligos (targeting 15 
genes), which had shown differential activity (d < -3σ) 
in the primary screening were confirmed by manual 
transfection (d < -2σ). All of 49 oligos which were not 
found to be differentially active in the screening run 
(d > -3σ) were confirmed as such by manual transfections 
(d > -2σ). Overall, the phenotype of 67 out of 84 oligos 
was confirmed. Representative images of outgrown 
colonies from the confirmatory study are shown in Figure 
2B and the corresponding quantifications are reported 
in Figure 2C. The list of confirmed hits is shown in 
Table 1: 3 genes were confirmed with 2 oligos (MASTL, 
Figure 1: siRNA screening results. A. Representative colony plates generated by transfecting Nthy-ori 3–1 (left) and BCPAP (right) 
cell lines with the same siRNA oligo mother plate. a. siRNA oligo lethal for both cell lines (blue); b. siRNA oligo selectively lethal for 
BCPAP (green); c. controls (yellow). B. Scatter plot of Colony Formation (CF) values obtained from 25139 unique siRNA oligos transfected 
in Nthy-ori 3–1 and BCPAP, reported as % of growth respect to NT for inter-plate data normalization (dot are the averages of two technical 
replicates performed in both cell lines). The mean d value (μ) is represented by a red line (dashed red lines: +/− 3σ). C. Scatter plot of 
normalized CF values showing the negative controls (siNT, blue), the lethal hits (green) and the differential hits (red). Insert: distribution 
of normalized d values after sigma binning.
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PLA2G15 and COPE) and 12 genes were confirmed with 
1 oligo (RGS3, CCND1, RASD1, NUDT9, OXTR, BRAF, 
COPZ1, MAP4K5, EPHB4, DNM3, REM2, SRPK1). 
Functional annotation analysis indicates that these genes 
are involved in several biological processes, such as cell 
cycle control, DNA damage and cell death, vesicular 
transport and endocytosis, cellular metabolic processes 
and intracellular signal transduction (Table 1). Network 
analysis performed by Ingenuity Pathway Analysis (IPA) 
identified two major connection networks as reported in 
Figure S1B.
Molecular profiling of confirmed hit genes
The thyroid TCGA data set [4], including 496 PTC 
samples, 58 of which matched with normal thyroid, 
was interrogated for assessing the mutational status and 
the expression level of hit genes in PTC. As expected, 
oncogenic BRAF mutations were detected with high 
frequency, being present in 248 samples. No mutations 
affecting the other genes were detected, with the exception 
of a silent mutation in COPZ1 gene in one case (data not 
shown). Expression analysis of hit genes was investigated 
on the whole data set (data not shown), as well as on the 
58 matched tumor and normal samples (Figure 3); in 
both cases identical results were obtained. According to 
their expression levels, hit genes can be classified in three 
groups: 1) genes with significantly high overexpression 
in PTC vs normal thyroid: CCND1, RGS3, OXTR, 
RASD1, DNM3; 2) genes with equal or slightly different 
expression in PTC and normal thyroid: COPE, COPZ1, 
PLA2G15, SRPK1, REM2, EPHB4, BRAF; 3) genes that 
are significantly downregulated in PTC vs normal thyroid: 
MAP4K5, NUDT9, MASTL. No differences among 
different PTC variants (classical, follicular, tall cell) or 
tumor stage were observed (data not shown).
Data retrieved from the Cancer Cell Line 
Encyclopedia (http://www.broadinstitute.org/ccle/home) 
showed that all the hit genes are expressed in BCPAP cells, 
with levels ranging from “low” to “very high” (data not 
Figure 2: Confirmation of differentially active hits. A. Comparison between d values obtained from the screening (bottom) and 
from confirmation experiments (top) performed with 84 siRNA oligos targeting 28 genes selected among the top ranked hits (A, B and 
C: three oligos per gene). Non-targeting Oligo (siNT) and siRNA oligos against PSMC3 were respectively used as negative and positive 
controls of transfection. Values represent the means of two technical replicates. The thresholds used to define differentially active oligos 
are shown in red (d = 47.2 for screening and d = 49.8 for confirmations). B. Representative pictures of individual wells showing colony 
formation in confirmation experiments after transfection of Nthy-ori 3–1 and BCPAP cells with the indicated siRNA oligos. C. Colony 
Formation (% siNT) values from image acquisition in B. All 84 oligos used for confirmation are shown; among these, oligos corresponding 
to the 15 genes are reported in B and are highlighted in color with standard deviation bars.
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Table 1. List of the confirmed hits after the primary screening.
Gene 
Symbol
Full Gene Name Accession GO-BP Term Confirmed 
active 
oligos
d (active oligos)
MASTL
microtubule 
associated serine/
threonine kinase-like
NM_032844
GO:0006468 protein 
amino acid phosphorylation 
GO:0006793 phosphorus 
metabolic process
2/2 33.75 (B) - 47.36 (A)
PLA2G15 phospholipase A2, 
group XV
NM_012320
GO:0006575 cellular amino 
acid derivative metabolic 
process  
GO:0006643 membrane lipid 
metabolic process
2/2 40.56 (B) - 47.71 (A)
COPE
coatomer protein 
complex, subunit 
epsilon
NM_007263
GO:0006890 retrograde 
vesicle-mediated transport, 
Golgi to ER transport 
GO:0051640 organelle 
localization
2/2 47.40 (C) - 48.45 (B)
RGS3 regulator of 
G-protein signaling 3
NM_017790
GO:0000165 MAPKKK 
cascade 
GO:0008277 regulation of 
G-protein coupled receptor 
proteinsignaling pathway
1/1 28.04 (A)
CCND1 Cyclin D1 NM_053056
GO:0000075 cell cycle 
checkpoint 
GO:0000077 DNA damage 
checkpoint
1/2 35.57 (C)
RASD1
RAS, 
dexamethasone-
induced 1
NM_016084
GO:0007264 small GTPase 
mediated signal transduction 
GO:0016481 negative 
regulation of transcription
1/1 36.74 (C)
NUDT9
nudix (nucleoside 
diphosphate linked 
moiety X)-type motif 
9
NM_024047
GO:0006163 purine nucleotide 
metabolic process 
GO:0006811 ion transport
1/1 45.6 (B)
OXTR oxytocin receptor NM_000916
GO:0000165 MAPKKK 
cascade 
GO:0003012 muscle system 
process
1/1 46.59 (C)
BRAF
v-raf murine sarcoma 
viral oncogene 
homolog B1
NM_004333
GO:0000165 MAPKKK 
cascade 
GO:0010941 regulation of cell 
death
1/1 47.45 (C)
COPZ1
coatomer protein 
complex, subunit 
zeta 1
NM_016057
GO:0006886 intracellular 
protein transport 
GO:0006890 retrograde 
vesicle-mediated transport, 
Golgi to ER
1/1 47.46 (A)
(Continued )
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Gene 
Symbol
Full Gene Name Accession GO-BP Term Confirmed 
active 
oligos
d (active oligos)
MAP4K5
mitogen-activated 
protein kinase kinase 
kinase kinase 5
NM_006575
GO:0000165 MAPKKK 
cascade 
GO:0001932 regulation 
of protein amino acid 
phosphorylation
1/1 47.88 (C)
EPHB4 EPH receptor B4 NM_004444
GO:0007169 transmembrane 
receptor protein tyrosine 
kinase signaling pathway 
GO:0045765 regulation of 
angiogenesis
1/1 48.98 (A)
DNM3 dynamin 3 NM_015569
GO:0006897 endocytosis 
GO:0010324 membrane 
invagination
1/1 49.29 (A)
REM2
RAS (RAD and 
GEM)-like GTP 
binding 2
NM_173527
GO:0006355 regulation of 
transcription, DNA-dependent 
GO:0007264 small GTPase 
mediated signal transduction
1/2 49.33 (B)
SRPK1 SFRS protein kinase 
1
NM_003137
GO:0006396 RNA processing 
GO:0007243 protein kinase 
cascade
1/2 49.80 (B)
PARP15
poly (ADP-ribose) 
polymerase family, 
member 15
NM_152615 0/1 −
RPS6KC1
ribosomal protein 
S6 kinase, 52kDa, 
polypeptide 1
NM_012424 0/1 −
RIPK3
receptor-interacting 
serine-threonine 
kinase 3
NM_006871 0/1 −
CAPN13 calpain 13 NM_144575 0/1 −
GNG7
guanine nucleotide 
binding protein (G 
protein), gamma 7
NM_052847 0/1 −
TAOK2 TAO kinase 2 NM_004783 0/2 −
UBE2E2
ubiquitin-conjugating 
enzyme E2E 2 
(UBC4/5 homolog, 
yeast)
NM_152653 0/1 −
TUFM
Tu translation 
elongation factor, 
mitochondrial
NM_003321 0/1 −
MMAA
methylmalonic 
aciduria (cobalamin 
deficiency) cblA type
NM_172250 0/1 −
GRPR gastrin-releasing peptide receptor NM_005314 0/1 −
(Continued )
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shown). Mutation analysis data indicated a low number 
(50/1651) of mutated genes in BCPAP cells. Cyclin D1, 
MASTL, MAP4K5, SRPK1 and EPHB4 genes were found 
to be of wild-type status, whereas no information was 
available for the remaining hit genes. These findings 
suggest that the addiction of BCPAP cells to the activity 
of the hit genes is unlikely related to alterations of the 
cognate proteins caused by mutations.
Hit gene expression in thyroid cell lines
We investigated the expression of 10 genes (the top 
11 hits except BRAF, see Table 1), in the normal (Nthy-ori 
3–1) and tumor (BCPAP) cell lines used for the siRNA 
library screening, as well as in a panel of thyroid tumor 
cell lines, representative of different tumor histotypes, 
and/or carrying different oncogenes: PTC-derived 
(TPC-1, carrying the RET/PTC1 oncogene); FTC-derived 
(WRO82–1); ATC-derived (8505C and HTC/C3, carrying 
the BRAFV600E oncogene; KAT-18). The expression 
of MASTL, PLA2G15, COPE, Cyclin D1, COPZ1 and 
MAP4K5 was investigated by western blot analysis 
(Figure 4A). Cyclin D1 was found to be 1.3 to 2.7 fold 
overexpressed in 6 out of 7 tumor cell lines with respect 
to Nthy-ori 3–1, with the exception of KAT-18, in which 
it was found less expressed. For COPE a slight increase in 
the protein expression levels in tumor cells, except KAT-
18, with respect to Nthy-ori 3–1 was observed. MASTL 
was found frequently less expressed in tumor cells, in 
keeping with what was observed by gene expression 
analysis in tumor samples (Figure 3). COPZ1 protein 
expression was slightly increased in all the tumor cell 
lines, and greater in 8505C. PLA2G15 expression was 
slightly reduced in all the tumor cell lines, except BCPAP, 
and strongly reduced in KAT-18. For MAP4K5, a slight 
increase in BCPAP, WRO82–1 and 8505C, and a decrease 
in the remaining cell lines were observed.
The expression of RASD1, NUDT9, RGS3 and 
OXTR genes was investigated by RT-PCR, as we failed 
to unequivocally detect the specific protein by western 
blot analysis (data not shown). As shown in Figure 4B, 
the genes are expressed in all the cell lines analyzed, and 
no differences can be appreciated.
Hit validation in BCPAP cell line
Among the candidate BCPAP vulnerability genes 
identified by the screening we selected CCND1, MASTL 
and COPZ1 for a validation study using commercially 
available siRNAs, different from those of the library 
screening. Four different oligos for MASTL, and a smart 
pool of oligos for CCND1 and COPZ1 were used (details 
are reported in Table S4). Firstly, the efficiency of gene 
knock-down was evaluated by investigating the expression 
of corresponding proteins in Nthy-ori 3–1 cells transiently 
transfected with specific siRNAs and with non-targeting 
oligos (siNT) as control (Figure 5A). For MASTL the 
highest silencing efficiency was obtained with oligos 1 
and 4 (89 and 95% of inhibition at 72 hours, respectively). 
siRNA targeting COPZ1 and CCND1 completely 
abrogated protein expression. Of note, in keeping with the 
siRNA library screening results, no macroscopic effects 
on Nthy-ori 3–1 cell growth/survival were observed (data 
not shown).
To investigate the effect of MASTL, CCND1 and 
COPZ1 gene silencing on BCPAP and Nthy-ori 3–1 cell 
viability, cells were transfected in 96 well plates with the 
different oligos above described, or with NT and PSMC3 
siRNAs as controls, and analyzed by CellTiter-Glo 
assay 10 days later. Scatter plots in Figure 5B represent 
the luminescence signal (average of two replicates, 
normalized with respect to siNT) of cells transfected with 
each siRNA oligo. siMASTL#1, siMASTL#4, siCCND1 
and siCOPZ1 reduced cell viability by 60%, 93%, 94% 
and 86%, respectively, an efficiency comparable to 
that of the control siRNA PMSC3 (93%). No effects 
were observed for siMASTL#2 and siMASTL#3, in 
keeping with their low silencing efficiency (Figure 5A). 
Gene 
Symbol
Full Gene Name Accession GO-BP Term Confirmed 
active 
oligos
d (active oligos)
CPT1C
carnitine 
palmitoyltransferase 
1C
NM_152359 0/1 −
GPX7 glutathione 
peroxidase 7
NM_015696 0/1 −
CCRK cell cycle related 
kinase
NM_012119 0/1 −
Genes are listed according to the number of active oligos; A, B and C represent three different oligos targeting the same gene. 
d values (<49.8) for each oligo, from the confirmation experiment, are also reported. NM: RefSeq Accession Number (http://
www.ncbi.nlm.nih.gov/refseq/about/). Representative Gene Ontology-Biological Process (GO-BP) terms are selected for each 
of the 15 validated genes, by means of DAVID6.7 functional annotation analysis.
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The effect of MASTL, CCND1, COPZ1 gene silencing 
in BCPAP cells was further confirmed by a different 
experimental approach. Cells were transfected in 6-well 
plates with the oligos which showed efficient silencing in 
the previous experiment (siCCND1 and siCOPZ1 smart 
pools, siMASTL #1 and #4 oligos), and the newly in 
house synthesized MASTL oligo #5 (see Figure S2 for 
silencing efficiency). Six days later the effect of MASTL, 
COPZ1 and CCND1 silencing on both cell growth and cell 
viability was evident by microscope observation: silenced 
BCPAP cultures were less confluent than control (siNT); 
in addition, they presented numerous floating (most likely 
dead) cells (Figure 5C). Trypan blue exclusion assay 
showed a reduction of cell growth by 69.5%, 59.7% and 
71% for siMASTL#1, #4 and #5, respectively; by 99.6% 
for siCOPZ1, by 91.5% for siCCND1 in comparison with 
the control (siNT). Western blot analysis performed at 
the end point of the experiment (Figure 5E) showed the 
complete abrogation of MASTL and Cyclin D1 protein 
expression. The same analysis was not feasible for COPZ1: 
due to the massive lethal effect of siCOPZ1, an insufficient 
amount of protein extract was recovered (data not shown).
Overall these results confirmed the growth inhibitory 
effect of Cyclin D1, MASTL, and COPZ1 gene silencing, 
thus providing evidence that BCPAP cells are addicted to 
the activity of these genes.
Effect of Cyclin D1, MASTL and COPZ1 gene 
silencing on different thyroid tumor cell lines
Irrespective of the specific oncogenic driving lesion 
and histotypes, thyroid tumors may share common effector 
Figure 3: Hit gene expression levels in PTC. Box plot distribution of RNAseq normalized expression values from the thyroid 
TCGA dataset of 15 selected genes in 58 matched normal (N) and PTC samples; A, B and C. represent genes overexpressed, equally or 
downregulated in PTC vs normal samples, respectively. The statistical significance of differences among the groups was assessed using 
Wilcoxon test.
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pathways for sustaining their transformed phenotype. To 
assess whether the survival genes confirmed in BCPAP 
cells are involved in such common pathways, we 
investigated the effect of CCND1, MASTL and COPZ1 
gene silencing in a panel of thyroid tumor-derived cell 
lines representative of different tumor histotypes.
Cell lines were transfected in 96 well plates with 
oligos targeting MASTL, CCND1 and COPZ1 genes and 
analyzed by CellTiter-Glo assay 10 days later. As reported 
in Figure 6A, gene silencing induced variable extents 
(15–95%) of cell growth inhibition in the majority of cell 
lines tested; no effect of CCND1 silencing in 8505C and 
KAT-18 cells, and of MASTL silencing in KAT-18 was 
observed. We also assessed viability of cells transfected 
in 6-well plates by trypan blue exclusion assay performed 
four-seven days after siRNAs transfection. As reported 
in Figure 6B, in all the cell lines analyzed (except KAT-
18), MASTL, COPZ1 and CCND1 gene silencing led to 
a significant decrease of cell viability: by 30–63% for 
siMASTL#1, by 35–75% for siMASTL#4, by 40–75% for 
siMASTL#5, by 75–99% for COPZ1 and by 70–94% for 
siCCND1. KAT-18 cells were found to be less sensitive to 
all the siRNA oligos: we found a decrease of cell growth 
by 31% for siMASTL#1, by 53% for si siCOPZ1 and by 
43% for CCND1, and by 52.3% for the siPSMC3 control, 
and no effect for siMASTL#4 and #5. The reduction of 
cell growth in all the cell lines was also documented by 
images taken before cell count: silenced cells appeared less 
confluent in comparison with the control, and presented 
variable fractions of detached and floating cells (Figure 
S3). Concomitantly, western blot in Figure 6C shows the 
high efficiency of MASTL, CCND1 and COPZ1 silencing 
in the same samples. The same analysis was not feasible 
for TPC1 cells transfected with siCOPZ1, due to massive 
lethal effect (data not shown). Importantly, this experiment 
revealed a growth inhibitory effect of CCND1 silencing 
in 8505C and KAT18, and of MASTL silencing in KAT18 
cells, which was not previously observed. This could be 
ascribed to variability in the experimental conditions and/
or silencing efficiency.
Figure 4: Hit gene expression in different thyroid tumor cells. A. Western blot analysis of MASTL, Cyclin D1, COPZ1, 
MAP4K5, PLA2G15 and COPE protein expression in a panel of thyroid cell lines; values represent band intensity, assessed by densitometry 
analysis, reported as the ratio to actin (loading control) and normalized for the Nthy-ori 3–1 value. B. RGS3, RASD1, NUDT9 and OXTR 
mRNA expression by RT-PCR in a panel of thyroid cell lines; GAPDH was used as housekeeping control. One out of three representative 
experiments is shown.
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We next performed some experiments to further 
corroborate the dependency of thyroid cancer cells upon 
Cyclin D1, MASTL and COPZ1 activity.
We tested thyroid tumor cell lines for susceptibility 
to palbociclib (PD-0332991), a specific inhibitor of 
Cyclin D1 associated kinases CDK4/6 [19]. Treatment 
with increasing doses of palbociclib showed a consistent 
antiproliferative effect in thyroid cancer cells, with an IC
50
 
value ranging from <0.003 μM for BCPAP cells to 0.20 
μM for HTC/C3 cells (Figure 7A and 7B). Representative 
images of thyroid cancer cell lines untreated or treated 
with 2.2 μM palbociclib for 72 h are reported in Figure 7C.
It has been reported that inhibition of MASTL induces 
multiple mitotic defects [20]. To investigate this issue in 
MASTL-depleted thyroid tumor cells, we performed the 
analysis reported in Figure 8. Asynchronous 8505C cells 
Figure 5: Effect of MASTL, CCND1 and COPZ1 silencing on BCPAP cells. A. Western blot analysis of MASTL, Cyclin D1 
and COPZ1 protein expression in Nthy-ori 3–1 cells, transiently transfected with siRNAs; actin was used as loading control. B. Scatter plot 
graph representing the percentage of cell growth (luminescence signal by CellTiter-Glo assay), normalized to that of Non Targeting oligo 
(siNT) 100%, 10 days after siRNA transfection in Nthy-ori 3–1 and BCPAP cells; siPSMC3 was used as positive control; one out of three 
representative experiments is shown. C. Representative pictures at 10X magnification of BCPAP cells 6 days after siRNA transfection. 
D. Cell proliferation assay of BCPAP cells 6 days after siRNAs transfection; the growth rate was determined by the trypan blue exclusion 
assay. Cell count of viable cells was normalized to that of siNT (100%); data represent the mean +/− sd of two independent experiments; 
the asterisks indicate differences significant by the unpaired Student’s t-test (**P < 0.01, ***p < 0.001). E. Western blot analysis of MASTL 
and Cyclin D1 expression performed in the same samples of panel D; actin was used as loading control for cell extracts.
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were transfected with the siMASTL or NT siRNA oligos 
and, 48 hours later, analyzed by immunofluorescence for 
β-tubulin, phospho-histone H3, and DNA for the presence 
of mitosis and nuclei aberrations. Several abnormalities 
associated with MASTL knockdown [20] were observed 
in MASTL-depleted 8505C cells. These include: 
Figure 6: Effect of CCND1, MASTL and COPZ1 silencing on different thyroid tumor cell lines. A. Scatter plot graph 
representing the percentage of cell growth (luminescence signal by CellTiter-Glo assay), normalized to that of Non Targeting oligo (siNT) 
100%, 10 days after siRNA transfection in a panel of thyroid cell lines; siPSMC3 was used as positive control. One out of three representative 
experiment is shown. B. Cell proliferation assay 4 days (for TPC1, 8505C and HTC/C3 cells), 5 days (for KAT-18 cells), 6 days (for BCPAP 
cells), 7 days (for WRO82–1 cells) after siRNAs transfection; the growth rate was determined by the trypan blue exclusion assay. Cell 
count of viable cells was normalized to that of siNT (100%); data represent the mean +/− sd of two independent experiments; the asterisks 
indicate differences significant by the unpaired Student’s t-test (*P < 0.05, **P < 0.01, ***p < 0.001). C. Western blot analysis of MASTL, 
Cyclin D1 and COPZ1 expression performed in the same samples of panel B; actin was used as loading control for cell extracts.
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multinuclear cells (panel B); abnormal mitotic figures, 
documented by the presence of condensed chromosomes 
that did not correctly align to metaphase plate (panel 
C); and chromatin bridges connecting daughter cells 
during anaphase (panel D). None of these abnormalities 
was observed in the control siNT cells (panel A). These 
results suggest that the growth inhibitory effect of MASTL 
silencing in thyroid tumor cells may be the consequence of 
failure of correct cell division process.
Shtutman et al [21] have recently reported that tumor 
cell COPZ1 vulnerability is related to downregulation of 
the paralogous COPZ2 gene. To assess whether this occurs 
also in thyroid tumor cells we investigated the expression 
of COPZ2 by Real Time PCR (Figure 9). With respect to 
control Nthy-ori 3–1 all the tumor cell lines analyzed, but 
WRO 82–1, showed downregulation of COPZ2 mRNA. 
This result indicates that for the majority of thyroid 
tumor cell lines the COPZ1 dependence may result from 
downregulation of COPZ2.
Collectively, our study identified Cyclin D1, 
MASTL and COPZ1 as thyroid cancer cell specific 
vulnerabilities, suggesting that they could provide a 
common therapeutic target in thyroid cancer treatment.
DISCUSSION
Despite much progress having been made in 
the genetic and molecular characterization of thyroid 
carcinoma, few or no therapeutic options are currently 
available for patients with aggressive and iodine-refractory 
thyroid tumors. Kinase inhibitors (KIs) in particular 
are being intensively studied in clinical trials in thyroid 
cancer: of note, various BRAF inhibitors for tumors that 
bear mutation of this gene [22–24], as well as a series 
of multi-kinase inhibitors, are emerging as potentially 
effective options in the treatment of advanced TC that 
are not responsive to traditional therapies [10]. However, 
the efficacy of KIs in patients with differentiated thyroid 
Figure 7: Thyroid cancer cell line sensitivity to palbociclib. A. Proliferation dose response curves of thyroid cancer cell lines 
treated with palbociclib for 72 hours. Nuclei were stained with Hoechst and counted in each well by means of an ArrayScan high-content 
screening reader. The cell count per field, derived from nuclear staining, was reported as proliferative parameter and normalized with respect 
to untreated controls (100%). Each value represents the mean and standard deviation of two replicates. B. IC50 values (μM) obtained using 
a sigmoid function for nonlinear interpolation of experimental points; for KAT-18, the IC50 value was derived from graphical analysis. 
C. Representative ArrayScan fields of the thyroid cancer cell lines untreated (CTRL) or treated with 2.2 μM palbociclib for 72 h and stained 
with Hoechst (bar = 50 μm).
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carcinoma has given contrasting evidence in the clinical 
trials, probably due to the drug resistance (as in other 
tumor types). Furthermore, KIs might cause significant 
side effects. This underlines the need for further efforts 
aimed at the identification of novel therapeutic approaches 
for thyroid tumors [10].
Large-scale siRNA-based functional screening 
on cancer cell lines are nowadays widely used for 
the identification of tumor cells vulnerabilities to be 
explored for therapeutic purposes [12]. Interestingly, 
such approaches allow the discovery of target genes 
that are required by tumor cells in specific contexts, 
thus providing the premise for the identification of 
therapeutic approaches with no or limited effect on 
normal cells.
In this paper, we described, for the first time, 
a high-throughput siRNA phenotypic screening 
campaign for the identification of thyroid tumor cell 
vulnerabilities. By screening a “druggable genome” 
siRNA library, we identified 398 siRNA oligos (targeting 
386 genes) which preferentially inhibited the growth 
of the BCPAP papillary thyroid cancer cell line as 
compared to that of non-transformed thyrocytes (Nthy-
ori 3–1). Fifteen out of 28 hit genes were technically 
confirmed. The relevance of this screening study and 
its ability to identify bona fide cell vulnerabilities is 
supported by two lines of evidence. First, BRAF was 
detected among the top BCPAP vulnerability genes. This 
was expected, as the dependency of BCPAP cells upon 
BRAFV600E oncogene has been previously documented 
[16]. Second, the screen efficiently detected genes that 
were indiscriminately lethal for both the Nthy-ori 3–1 
and BCPAP cell lines: in many cases, these were found 
to be genes that encode proteins of essential function 
and have been identified as survival genes in previous 
functional screenings [14, 18, 25].
Figure 8: MASTL silencing causes abnormal mitotic figures. 8505C cells transfected with the indicated siRNAs were analyzed 
by immunofluorescence for β-tubulin (green), phospho-histone H3 (red) and DAPI (DNA, blue). Arrows indicate normal mitosis 
(A), multinuclear cell (B), condensed chromosomes not correctly congressed to metaphase plate (C), DNA bridge (D) (Magnification 40x).
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Analyzing the thyroid TCGA data set, we found 
no mutations affecting the confirmed hit genes, besides 
BRAF, suggesting that functional alterations in PTC may 
be excluded. With respect to gene expression the hit genes 
were found to be either equally or differentially (both 
upregulated and downregulated) expressed in PTC in 
comparison with normal samples.
Three hit genes, namely Cyclin D1, MASTL and 
COPZ1, were selected for further confirmation. Their 
vulnerability for BCPAP cells was confirmed by using 
siRNA oligos different from the screening. Interestingly, 
we showed that the silencing of Cyclin D1, MASTL 
and COPZ1 reduces the growth and survival of several 
different TC cell lines, regardless the histotype and the 
oncogenic lesion.
Cyclin D1 is an important cell cycle regulator 
that promotes G1/S phase transition by activation of 
CDK4 and CDK6 kinases [26]. Cyclin D1 is frequently 
overexpressed in human cancer, and it has been proposed 
as a therapeutic target. Several approaches aimed at its 
inhibition are presently ongoing. As for all cyclins, while 
the lack of enzymatic activity makes direct targeting of 
Cyclin D1 difficult, a much more amenable approach is 
to target cyclin functions by inhibition of their associated 
kinases. Indeed, several CDK4/6 inhibitors have shown 
promising antitumor activity in experimental systems, and 
are presently under clinical evaluation for different tumor 
types [26]. Alternative approaches are also currently under 
investigation, including the targeting of factors which 
regulate Cyclin D1 protein turnover, such as the USP2 
deubiquitinase [27]. In thyroid carcinoma overexpression 
of Cyclin D1 at mRNA and protein level has been 
documented, and has been suggested to contribute to 
tumor progression [28–30]. However, no functional data 
dissecting the role of Cyclin D1 in thyroid tumorigenesis 
are available. We found that Cyclin D1 inhibition led to a 
consistent reduction of cell growth in all the thyroid tumor 
cell lines analyzed. This was not associated with Cyclin D1 
expression level, suggesting that the dependency of 
thyroid tumor cells upon Cyclin D1 activity may not 
require aberrant protein expression. We also found that 
all the thyroid tumor cell lines are sensitive to palbociclib 
(PD-0332991), a selective CDK4/6 inbititor approved for 
the treatment of ER+/HER2- breast cancer in combination 
with letrozole [31]. Whether the antiproliferative effect 
after Cyclin D1 silencing or palbociclib treatment in 
thyroid tumor cells, but not in normal ones, is related 
to the presence of functional pRB, as reported for other 
tumor types [19], remains to be investigated. Our studies 
identified Cyclin D1 as a therapeutic target for thyroid 
tumors, and provide a rationale for preclinical and clinical 
studies aimed to assess the efficacy of inhibitors of 
Cyclin D1 function in thyroid cancer.
MASTL (Microtubule associated serine/threonine 
kinase-like) regulates mitosis progression by inhibiting 
PP2A/B55δ, the principal protein phosphatase complex 
that dephosphorylates CDK1 substrates. MASTL activity 
is essential for prevention of defects in chromosome 
condensation and segregation, prometaphase arrest and 
mitotic collapse during cell division [32]. Furthermore, 
it modulates DNA damage response by promoting 
checkpoint recovery and cell cycle progression [33]. 
Little is known about MASTL in cancer. Nagel et al. 
[34] reported that the knockdown of MASTL, through 
promoting defects in in cytokinesis and a shortened G2/M 
phase arrest, is capable of sensitizing lung cancer cells 
to radiations. Notably, MASTL inhibition affects tumor 
cell but not normal primary fibroblast radiosensitivity, 
thus suggesting that MASTL could represent a druggable 
target to combine with radiotherapy. In head and neck 
carcinoma MASTL was found involved in progression and 
recurrence and proposed as therapeutic target [35]. We 
Figure 9: Expression of COPZ2 in thyroid tumor cell lines. Real-time PCR analysis of COPZ2 gene expression; results are 
presented as log10-transformed relative quantity (RQ) of COPZ2 mRNA normalized for HPRT1 housekeeping gene expression. Data 
represent the mean +/− sd of three independent experiments.
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have identified MASTL as vulnerability gene for thyroid 
carcinoma. In fact, MASTL silencing interfered with the 
growth of all thyroid cell lines, although with variable 
extents. Moreover, evidence of failure of correct cell 
division process was found in MASTL-depleted cells. 
Of note, our study identified MASTL as a novel mitotic 
machinery target in thyroid tumor, in addition to PLK1 and 
AURKs, both overexpressed and proposed as therapeutic 
targets in ATC [36, 37]. Remarkably, we found that 
MASTL vulnerability in thyroid tumor cell lines is not 
associated with overexpression; on the contrary, MASTL 
is slightly downregulated in PTC samples and in thyroid 
tumor cells. Overall these findings highlights the need of 
further investigation in order to assess whether MASTL 
may represent a useful target in different tumor types, as 
well as the search/design of strategies to block the activity 
of MASTL, for which no specific inhibitors have been so 
far identified.
COPZ1 (coatomer protein complex ζ1) is a subunit 
of coatomer protein complex I (COPI), a secretory vesicle 
coat protein complex involved in Golgi apparatus and 
endoplasmic reticulum traffic, endosome maturation, 
autophagy [38, 39] and lipid homeostasis [40]. COPZ1 has 
been proposed as a tumor-specific gene target. It has been 
shown that tumor cells become dependent on COPZ1, as 
a result of a tumor-specific downregulation of its isoform 
COPZ2 [21]. Interestingly, COPZ1 knockdown kills both 
proliferating and non-dividing tumor cells, but does not 
affect normal cells, thus suggesting that COPZ1-targeting 
therapies have the potential for eradicating cancer cells, 
independently of whether they are actively proliferating. 
Our screening and validation identified COPZ1 as a 
thyroid tumor cell specific survival gene. Interestingly, 
we also found a significant downregulation of COPZ2 
mRNA expression in the majority of thyroid tumor cell 
lines. An exception is represented by WRO82–1 which, 
despite expressing COPZ2 mRNA levels higher than 
control, is sensitive to COPZ1 silencing. This raises the 
possibility that other mechanisms, in addition to COPZ2 
downregulation, may be involved in determining tumor 
cell COPZ1 dependency. Whether the thyroid tumor cell 
dependency upon COPZ1 is related to downregulation 
of COPZ2 isoform, or to deregulation of other COPI 
components, as well as the modalities through which 
COPZ1 inhibition leads to growth suppression of thyroid 
tumor cells, remains to be investigated.
In conclusion, by a siRNA-based functional 
screening we have identified a signature of vulnerability 
for thyroid carcinoma cells, thus identifying novel 
potential therapeutic targets in this setting. Further 
characterization of three hit genes, namely Cyclin D1, 
MASTL and COPZ1, demonstrates that their abrogation 
selectively impairs the growth of several thyroid tumor 
cell lines, irrespective of the histotype or driving genetic 
lesion, thus indicating that they represent common 
examples of “non-oncogene addiction” in thyroid 
cancer. Variable extents of cell growth inhibition among 
the cell lines upon silencing of these target genes were 
observed. Whether these differences are related to 
genetic background and/or intrinsic sensitivity to cell 
death remains to be investigated. The dependency upon 
Cyclin D1, MASTL and COPZ1 activity is restricted to 
tumor cells and not normal thyroid cells, as previously 
reported for other tumor types [21, 27, 34, 35]. Thus 
we envisage that Cyclin D1, MASTL and COPZ1 are 
attractive targets for new therapeutic approaches for 
thyroid cancer which spare normal cells and which would 
thus have limited side effects.
MATERIALS AND METHODS
Cell lines
Nthy-ori 3–1 cell line (SV-40 immortalized 
normal human thyroid follicular cells) was purchased 
from European Collection of Cell Cultures (ECACC) 
(Salisbury, UK); BCPAP, TPC-1, WRO82–1, 8505C, 
KAT-18 were obtained from Prof. A. Fusco (University 
Federico II, Naples, IT); HTC/C3 was purchased from 
Riken Cell Bank (Tsukuba, Japan).
Nthy-ori 3–1 and the PTC-derived BCPAP cell 
lines were cultured in RPMI 1640 medium (Gibco Life 
Technologies, Carlsbad, CA, USA) supplemented with 
10% (v/v) heat-inactivated fetal bovine serum (FBS) 
(EuroClone, Pero, Italy), penicillin (100 U/ml) and 
streptomycin (100 mg/ml). The other cell lines PTC-
derived TPC1; FTC-derived WRO82-1; ATC-derived 
8505C, KAT18 and HTC/C3 were maintained in DMEM 
(Gibco, Life Technologies, Carlsbad, CA, USA) medium 
containing 10% FBS and 2 mM glutamine. All cell 
lines were cultured as monolayer at 37°C in a 5% CO
2
 
humidified atmosphere.
Cell lines were genotyped at the Fragment 
Analysis Facility of Fondazione IRCCS Istituto 
Nazionale dei Tumori, using Stem Elite ID System 
(Promega Corporation, Madison, USA) according to 
the manufacturer’s instructions and ATCC guidelines. 
The profiles obtained matched to their original profiles 
[41, 42]. WRO82–1 profile matched to that reported by 
Xu et al. [43] and HTC/C3 to that reported by JCRB 
Cell Bank (http://cellbank.nibio.go.jp/legacy/celldata/
jcrb0164.htm).
Mycoplasma contamination was tested periodically 
and found negative in all cell lines (PCR Mycoplasma 
Detection Set, TAKARA Bio Inc).
siRNA transfection optimization
Optimal conditions for reverse siRNA transfection 
of Nthy-ori 3–1 and BCPAP cells were determined by 
comparing cell viability after transfecting a positive 
control siRNA targeting the proteasome subunit PSMC3, 
and a negative control non-targeting oligo (siNT), in the 
presence of different cell densities and Lipofectamine 
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RNAiMAX reagent (Invitrogen Life Technologies 
Carlsbad, CA, USA) concentrations. The best reagent and 
transfection conditions were those that produced the least 
(<10%) cell loss with siNT, and the greatest (>90%) cells 
decrease with the lethal PMSC3 oligo.
High throughput siRNA screening
The human Silencer Select Druggable Genome 
siRNA Library V4 (Ambion Life Technologies, Carlsbad, 
CA, USA) is composed by 309 96-well plates containing 
25139 unique lyophilized siRNA oligos targeting 9031 
human genes (three oligos per gene, on average). Stock 
plates were obtained by dissolving oligonucleotides with 
100 μl of DEPC-treated water (Ambion Life Technologies, 
Carlsbad, CA, USA) (final concentration 2.5 μM) and 
by adding NT and PSMC3 siRNA oligos (2.5 μM) in 
alternate position in the empty column 12 of each plate 
(see Figure 1A). Library oligonucleotides were further 
diluted to 800 nM with DEPC-treated water (mother 
plates). Daughter plates were prepared by transferring 
17 μl/well of mother plate oligonucleotide solution in 
plates prefilled with 119 μl of Opti-MEM® I medium 
(Gibco Life Technologies, Carlsbad, CA, USA) containing 
4 μl/ml of lipofectamine® RNAiMAX. The solution was 
gently mixed by pipetting and incubated for 20 minutes 
room temperature, and then 30 μl/well were split into four 
transfection plates, to which 120 μl/well of cell suspension 
(1250 cells /ml) were added. Two plates for each cell line 
(Nthy-ori 3–1 and BCPAP) were used. Each well contained 
150 cells, 20 nM oligo, RNAiMAX 0.1% vol/vol. 
After transfection, plates were kept at room temperature 
for 15–20 minutes to minimize uneven distribution of 
the cells in each well [44], and then incubated at 37°C 
for 7–8 days by stacking in alternate orientations to limit 
uneven medium evaporation and to facilitate gas exchange. 
As a result of this procedure, no edge effects or evidences 
of asymmetric cell growth emerged from screening data 
analysis, and visual inspection of plate scans confirmed 
homogeneous cell distribution in all plates. The following 
custom-barcoded 96-well microplates purchased from 
Greiner Bio-One (Frickenhausen, Germany) were used: 
U-bottom microplate for mother and daughter plates; 
CELLSTAR®, Black /μClear® plate for transfection plates. 
All liquid handling and plate tracking were performed with 
a Freedom EVO® robotic platform (Tecan, Männedorf, 
Switzerland); disposable MCA384 Tips and reservoirs 
were purchased from Tecan.
siRNAs
Information on siRNAs used in the transfection 
setup, as control in the screening, or in confirmation 
and validation studies is summarized in the Table S4. 
Oligos produced in house were designed and synthesized 
with stabilizing modifications (i.e.: phosphorylation in 
5′ position of the antisense strand and 2′-O-methyl ribosyl 
substitution at position 2 of the sense strand) known to 
reduce off-target effect [45].
Colony formation assay (CFA)
Seven-eight days after transfection, cells were fixed 
with formaldehyde 3.7% v/v solution at room temperature 
for 30 minutes, washed with PBS and stained for 20 minutes 
with a PBS solution containing 0.05% v/v Triton® X-100 
(Sigma-Aldrich, St. Louis, MO, USA) and TO-PRO®-3 
iodide (Invitrogen Life Technologies (Carlsbad, CA, USA) 
diluted 1:1000. After a second wash, 50 μl PBS were left 
in each well. Plates were sealed and analyzed with an 
Odyssey® infrared scanner (LI-COR Biosciences, Lincoln, 
NE, USA) which provides whole-well fluorescence 
quantification of cells stained with TO-PRO®-3 dye. The 
fluorescence intensity (FI) was considered as readout, which 
is proportional to both colony number and size.
Screening data analysis
FI values were registered in a proprietary Oracle 
database through Symyx Assay Explorer® and matched with 
the library information. The FI of each sample was divided 
by the average FI of the three non-targeting oligos within 
the same plate (set as 100%) for interplate normalization. 
TIBCO SpotFire (Boston, MA, USA) and Microsoft Excel 
(Redmond, WA, USA) were used for statistical analysis and 
visualization of screening data distributions. The means and 
standard deviations of FI (% siNT) values and z*-scores [46] 
were calculated from the two technical replicates for each 
cell line and reported in  Table S1 (Excel file with screening 
results).
To identify genes whose RNAi-mediated inhibition 
affects the growth of BCPAP but not Nthy-ori 3–1 cells, a 
distance factor (d) expressed as:
 
d = "1100 − % NTONthy−ori 3−1 2 2 + 1% NTOBCPAP 2 2
was introduced. “d” represents the distance 
between the %NT value of any given siRNA oligo and 
the point of maximal lethality towards BCPAP without 
effects on Nthy-ori 3–1 (coordinate %NT
Nthy-ori 3–1
 = 100, 
%NT
BCPAP
 = 0). Screening hits were selected among 
siRNA oligos with significantly low d values, whereas 
oligos either equally inactive on both cell lines, or equally 
lethal on both cell lines, or preferentially lethal on Nthy-
ori 3–1, are excluded. Based on the distribution analysis 
of d scores, a -3σ threshold (corresponding to d = 47.2) in 
the primary screening, and a -2σ threshold (corresponding 
to d = 49.8) in the confirmation study, were applied to 
define hits.
Cell proliferation assay
Cells (500 cells/well) were reverse transfected 
in 96-well plate with 20 nM specific siRNAs using 
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the Lipofectamine RNAiMAX reagent, according to 
manufacturer’s instruction. Ten days later, cell viability 
was assessed by CellTiter-Glo Luminescent Cell Viability 
Assay (Promega Corporation, Madison, USA), performed 
as recommended by the supplier. Luminescence signals 
were acquired using a microplate reader (TecanUltra, 
Tecan Trading AG, Switzerland).
For the trypan blue exclusion assay, BCPAP and 
8505C (1 × 105), TPC-1 (6 × 104), WRO82–1, HTC/C3 
and KAT-18 (8 × 104) cells were transfected the day later 
in 6-well plate with 20 nM of specific siRNAs using 
Lipofectamine RNAiMAX, according to manifacturer’s 
instruction. At different days after transfection (4 days 
for TPC1, 8505C and HTC/C3 cells; 5 days for KAT-18 
cells, 6 days for BCPAP cells, 7 days for WRO82–1 cells) 
the fraction of viable and dead cells was analyzed. For 
palbociclib experiments, cells (8000 cells/well) were seeded 
in black/clear bottom 96-well plates and, the following 
day, treated with increasing doses of the palbociclib 
(PD 0332991) inhibitor (Selleck Chemicals, Houston, 
TX, USA, cat. S2768). After 72 hours, cells were fixed 
with 3.7% paraformaldehyde solution for 30 minutes at 
RT, washed and stained with 1 mg/ml Hoechst 33342. The 
plates were analyzed with an ArrayScan VTI high-content 
screening reader (Thermo-Fisher Scientific, Pittsburgh, 
PA): at least 800 cells were acquired in each well with a 
10X objective in one fluorescence channel (XF93 optical 
filter set). Cell nuclei were automatically recognized and 
counted in ten fields to estimate the cell number per well 
as proliferation readout. IC50 values were calculated by 
sigmoid curve fitting of experimental points.
Gene Ontology and gene expression analyses
The functional annotation analysis on the identified 
gene lists was performed by means of the Database for 
Annotation, Visualization and Integrated Discovery 
(DAVID) tool v6.7 (https://david.ncifcrf.gov/). Gene 
Ontology (GO) Biological Process (BP) and Molecular 
Function (MF) terms were used as annotation categories 
and medium classification stringency was set for the 
functional annotation clustering analysis. The annotation 
clusters with an Enrichment score (ES) >1.3 were selected 
and representative GO-terms were indicated for each 
significant cluster. To assess the interactions between the 
validated fifteen genes, network analysis was carried out 
using the Ingenuity Pathway Analysis Tool (Ingenuity® 
Systems, http://www.ingenuity.com). The Core Analysis 
function was used to compare genes pooled from literature 
and other molecules in IPA’s database.
The thyroid TCGA data set, containing the molecu-
lar data on nearly 500 PTC, is the largest data collection so 
far available (https://tcgadata.nci.nih.gov/tcga/tcgaCancer-
Details.jsp?diseaseType=THCA&diseaseName=Thyroid). 
Illumina HiSeq Level 3 data were downloaded from TCGA 
Data Portal and RSEM [47] gene normalized expression 
values of selected genes were derived for 58 PTC patients, 
in tumor and adjacent normal samples, respectively. The 
statistical significance of gene expression difference 
between PTC and normal groups was assessed using Wil-
coxon test.
RNA extraction, RT-PCR and Real time PCR
RNA extraction and RT-PCR were performed 
as previously described [48], using the follow-
ing primer: 5′-ATGAGAGGCCTGTGGAGCACT-3′ 
(forward), 5′-TCATGTGTCGACTTGCAGGAG-
3′(reverse) for RGS3 fragment amplification; 
5′-GCAGATCCTCAGATCAGTGAA-3′(forward), 
5′-TATAATGGGATCTGCAGCGTG-3′ (reverse) for 
NUDT9; 5′-CGAGGTCTACCAGCTCGACAT-3′ (for-
ward), reverse 5′-CACGTCCACGTTCTCCTTGGT-3′ 
(reverse) for RASD1; 5′-ATGTGGAGCGTCTGGGAT-
GC-3′ (forward), 5′-GCTCAGGACAAAGGAGGACG-3′ 
(reverse) for OXTR [49].
For Real Time PCR analysis 20 ng of retrotranscribed 
RNA were amplified in PCR reactions carried out in 
triplicate on an ABI PRISM 7900 using TaqMan gene 
expression assays (Applied Biosystem, Foster City, 
CA). Hs00212698_m1 was used for COPZ2 expression; 
human HPRT1 (HPRT-Hs99999909_A1) was used as 
housekeeping gene for the normalization among samples. 
Data analysis was performed using the SDS (Sequence 
Detection System) 2.4 software.
Western blot analysis
Western blot analysis was performed as previously 
described [48], using the following antibodies: anti-
Cyclin D1 (DCS-6: sc-20044, 1:500), anti-COPE, 
(E-20: sc-12104, 1:500), anti-PLA2G15 (LYPLA3, 
H-167: sc-135297, 1:500), anti-MAP4K5 (KHS, N-19: 
sc-6429, 1:1000), anti-COPZ1 (D-20: sc-13349, 1:750), 
anti-GAPDH (6C5, sc-3223: 1:2000) purchased from 
Santa Cruz, CA, USA; anti-MASTL (ab86387, 1:7000) 
from Abcam, Cambridge, UK; anti-β-actin (A2066, 
1:5000) and anti-vinculin (V9131, 1:1000) from Sigma-
Aldrich, St Louis, Mo, USA.
Immunofluorescence analysis
Cells growing on glass coverslips were transfected 
with 20 nM NT or MASTL siRNAs and, 48 hours later, 
fixed for 10 minutes with 4% paraformaldehyde (Sigma 
Aldrich, St Louis, Mo, USA). After permeabilization 
for 10 minutes with 1% BSA and 0.1% Triton X-100 in 
PBS, and incubation for 30 minutes with 1X blocking 
solution (2% BSA in PBS), cells were incubated with 
anti-β-tubulin (clone TUB 2.1: T4026, 1:400, Sigma 
Aldrich, St. Louis, MO, USA) or anti-histone H3 (phospho 
S10) (E173: ab32107, 1:1000, Abcam, Cambridge, 
UK) primary antibodies for 1 hour. After washing with 
PBS, cells were incubated with Alexa Fluor® 546 rabbit 
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(1:500, Invitrogen/Molecular Probes®) and Alexa Fluor 
488® mouse (1:500, Invitrogen/Molecular Probes®) 
secondary antibodies for 1 hour. Slides were then 
prepared using ProLong Diamond Antifade mountant 
with DAPI (P36966, Molecular Probes®) and imaged with 
immunofluorescence microscopy (Eclipse E1000; Nikon 
Instruments, Inc. NY, USA).
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